Atezolizumab (Tecentriq®) in combination with bevacizumab. HTA ID: 20060

Assessment Status NCPE Assessment Process Complete
HTA ID 20060
Drug Atezolizumab in combination with bevacizumab
Brand Tecentriq®
Indication For the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have not received prior systemic therapy.  
Assessment Process
Rapid review commissioned 21/12/2020
Rapid review completed 08/02/2021
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab in combination with bevacizumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 24/02/2021
Pre-submission consultation with Applicant 22/11/2021
Full submission received from Applicant 26/07/2022
Preliminary review sent to Applicant 24/11/2022
NCPE assessment re-commenced 22/12/2022
Factual accuracy sent to Applicant 08/03/2023
NCPE assessment re-commenced 15/03/2023
NCPE assessment completed 08/05/2023
NCPE assessment outcome The NCPE recommends that atezolizumab (Tecentriq ®) in combination with bevacizumab not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*.

Technical Summary

Plain English Summary

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.

The HSE has approved reimbursement following confidential price negotiations. March 2024